SmallerStandardBiggerPrintRSS FeedFollow TVM Capital on TwitterSearch

Life Sciences News

1 - 10 of about 1489 releases

Sep 02, 2010

Evotec Completes Acquisition of DeveloGen

Hamburg, Germany – 2 September 2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010. Following the successful fulfilment of various Closing conditions, the sellers of 99.3% of the shares in... (...)

Sep 02, 2010

Addex drug-candidate effective in Alzheimer’s disease model

Geneva, Switzerland, 2 September 2010 – Allosteric modulation company Addex Pharmaceuticals Ltd (SIX: ADXN) announced today that it has observed efficacy in a model of Alzheimer’s disease using a recently discovered orally-available drug-candidate. The proprietary molecule specifically inhibits a... (...)

Sep 01, 2010

EUSA PHARMA ANNOUNCES THE APPOINTMENT OF STEPHEN A. STAMP TO ITS BOARD OF DIRECTORS

Oxford, UK and Langhorne, PA, USA – 1 September 2010 EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Stephen A. Stamp to the company’s Board as an independent Non-Executive Director. Mr Stamp... (...)

Aug 25, 2010

Addex Partner Completes ADX71149 Phase I Program

Geneva, Switzerland, 25 August 2010 - Allosteric modulation company Addex Pharmaceuticals Ltd (SIX:ADXN) announced today that the Phase I studies required to commence Phase II testing of ADX71149 have been satisfactorily completed. Subject to regulatory authorizations, Phase IIa studies in... (...)

Aug 20, 2010

Anchor Therapeutics Secures $10 Million Series B Financing to Advance Pepducin Drug Candidates

Cambridge, MA - August 20, 2010 - Anchor Therapeutics today announced an initial closing of $10 million in a Series B financing. The investment is being led by current investors TVM Capital, HealthCare Ventures and the Novartis Option Fund. The company is in continuing discussions with additional... (...)

Aug 12, 2010

Strong Milestone Income Leads to Profitable 1st Half

DRUG DISCOVERY BUSINESS REPORTS STRONG REVENUE GROWTH (+33%) AND A POSITIVE OPERATING RESULT OF € 0.3 M; REVENUE GUIDANCE RAISED FOR THE FULL YEAR 2010 Hamburg, Germany - 12 August 2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today reported financial results and corporate updates for... (...)

Aug 10, 2010

Gregory Miller Joins Concert Pharmaceuticals as Head of Business and Corporate Development

August 10, 2010 Lexington, MA –– Concert Pharmaceuticals, Inc. today announced that Gregory L. Miller has joined the company as its new Head of Business and Corporate Development. In this role, Greg will focus on leading Concert’s business development efforts and play a key part in strategic... (...)

Aug 05, 2010

Agennix AG Provides Update on Development of Talactoferrin

Planegg/Munich (Germany), Princeton, NJ and Houston, TX, August 5, 2010 – Agennix AG (Frankfurt Stock Exchange: AGX) today provided an update on its development status and plans for oral talactoferrin. Enrollment on track in Phase III FORTIS-M trial in non-small cell lung cancer The Company... (...)

Aug 04, 2010

Evotec - Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received

Hamburg, Germany - 4 August 2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec. The milestone reached was the selection of a candidate compound for... (...)

Aug 03, 2010

Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering

NORTHBROOK, IL – August 3, 2010 – Horizon Pharma, Inc. announced today that it has filed a registration statement on form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be... (...)

Next results →